BioAge Labs (BIOA) 25th Annual Needham Virtual Healthcare Conference summary

Company overview and strategic priorities

• Focused on applying human aging biology to develop therapies for cardiometabolic diseases using a large human aging data platform and collaborations with major pharma companies.

• Lead program BGE-102 is an NLRP3 inflammasome inhibitor with novel chemistry, targeting cardiovascular risk reduction and ophthalmology (diabetic macular edema).

• Advancing two APJ agonist programs for obesity, showing promising preclinical results in combination with incretins.

• Key 2024 milestones include phase I completion, initiation of dose-ranging CV risk and DME POC trials, and IND filing for APJ agonist.

Pipeline and clinical data highlights

• BGE-102 shows anti-inflammatory effects comparable to IL-6 injectables, with strong reductions in hs-CRP, IL-6, and fibrinogen in phase I trials.

• Phase I MAD cohorts enrolled obese patients with elevated CRP, mirroring populations in key comparator trials.

• Safety profile to date is favorable, with only mild to moderate AEs, no dose-limiting toxicities, and high safety margins.

• Phase I data indicate strong target engagement and dose-dependent anti-inflammatory effects.

Market context and competitive landscape

• Significant investor and pharma interest in NLRP3 and inflammatory pathways, driven by recent acquisitions and positive trial readouts in the space.

• ZEUS (Novo’s IL-6) and CANTOS trials provide external validation for targeting inflammation in ASCVD.

• BGE-102’s oral administration and CNS/retinal penetrance offer differentiation versus injectables and non-penetrant drugs.